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Liver transplantation at Red Cross War Memorial Children's 
Hospital 
C W N Spearman, M McCulloch, A J W Millar, H Burger, A Numanoglu, E Goddard, P Gajjar, 
C Davies, E Muller, F McCurdie, D Kemm, S Cywes, H Rode, D Kahn 
The liver transplant programme for infants and children at Red 
Cross War Memorial Children's Hospital is the only established 
paediatric service in sub-Saharan Africa. Referrals for liver 
transplant assessment come from most provinces within Smith 
Africa as well as neighbouring countries. 
Patients and methods. Since 1987, 81 children (range 6 months 
- 14 years) have had 84liver transplants with biliary atresia 
being the most frequent diagnosis. The indications for 
transplantation include biliary atresia (48), metabolic (7), 
fulminant hepatic failure (10), redo transplants (3) and other 
(16). Four combined liver/kidney transplants have been 
performed. Fifty-three were reduced-size transplants with 
donor/recipient weight ratios ranging from 2:1 to 11:1 and .32 
children weighed less than 10 kg. 
Results. Sixty patients (74%) survived 3 months -14 years 
post transplant. Overall cumulative 1- and 5-year patient 
survival figures are 79% and 70% respectively. However, with 
the introduction of prophylactic intravenous ganciclovir and 
the exclusion of hepatitis B virus (HBV) IgG core Ab-positive 
The liver transplant programme for infants and children at Red 
Cross War Memorial Children's Hospital is at present the only 
established paediatric service in sub-Saharan Africa. The first 
paediatric transplant was performed on 6 December 1987 for 
end-stage liver disease due to alpha-1-antitrypsin deficiency. 
The patient unfortunately died of complications in January 
1988. The paediatric programme was then put on hold until 
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donors, the 1-year patient survival is 90% and the projected 
5-year paediatric survival is> 80%. Early(< 1 month) post-
liver-transplantmortality was low. Causes include primary 
malfunction (1), inferior vena cava thrombosis (1), bleeding 
oesophageal ulcer (1), sepsis (1) and cerebral oedema (1). Late 
morbidity and mortality was mainly due to infections: de novo 
hepatitis B (5 patients, 2 deaths), Epstein--Barr virus (EBV)-
related post-transplantation lymphoproliferative disease (12 
patients, 7 deaths) and cytomegalovirus (CMV) disease (10 
patients, 5 deaths). Tuberculosis (TB) treatment in 3 patients 
was complicated by chronic rejection (1) and TB-drug-induced 
subfulminant liver failure (1). 
Conclusion, Despite limited resources, a successful paediatric 
programme has been established with good patient and graft 
survival figures and excellent quality of life. Shortage of donors 
because of infection with HBV and human immunodeficiency 
virus (HIV) leads to significant waiting-list mortality and 
infrequent transplantation. 
S Afr Med J 2006; 96: 960-963. 
the adult programme had become established at Groote Schuur 
Hospital and was restarted in November 1991.1 Referrals for 
liver transplant assessment come from most provinces within 
South Africa as well as neighbouring countries. 
Patients and methods 
Since 1987, 84 orthotopic liver transplants have been performed 
on 81 children and all are included in this retrospective review. 
The major indication for liver transplantation was biliary 
atresia (57%) followed by acute liver failure (12%). There were 
4 combined liver /kidney transplants for primary hyperoxaluria 
(3) and congenital hepatic fibrosis associated with polycystic 
kidneys (1). 
Demographics. The age of the children ranged between 6 
months and 14 years (mean 4.6 years) and included 38 male 
and 43 female children. The racial distribution was as follows: 
14 black, 33 mixed race, 4 Asian and 30 white. Their weight 
ranged between 4 kg and 50 kg (mean 13 kg) and 32 children 
weighed < 10 kg. 
Indications for liver transplantation. The indications for 
liver transplantation are listed in Table I. 
Surgical techniques. The surgical techniques used for donor 
retrieval and recipient liver removal and engraftment have 
Table I. Indications for liver transplantation 
Biliary atresia 





























been previously described in detaiJ.l-3 Fifty-three reduced-size 
grafts were used (31 left lateral segment, 18 left lobe, 4 right 
lobe). In all the reduced-size livers and in patients with biliary 
atresia, choledochojejunostomy was used for biliary drainage 
without the use of stents or T-tubes. The donor: recipient 
weight ratios varied between 2:1 and 11:1 (mean 3.4:1.) One 
living related (mother-child) transplant was performed. 
Anaesthesia. The anaesthetic time ranged from 7 to 16 hours 
(mean 9 hours) and the mean blood volume transfused was 2.5 
blood volumes (range 0.5 - 5.7). Blood-group crossmatch was 
identical in 66, compatible in 16 and incompatible in 2 cases. 
Immunosuppression. Baseline immunosuppression 
consisted of triple therapy in the form of cyclosporin, 
methylprednisone and azathioprine. Oral cyclosporin (5 mg/ 
kg) was given immediately prior to surgery and continued 
postoperatively initially intravenously, but since 1997 it has 
been given orally, using Neoral cyclosporin 3 times a day 
aiming for a trough level of 350-400 ng/ml initially and a 2-
hour peak level greater than 1 000 ng/ml! Methylprednisolone 
(10 mg/kg) and azathioprine (0.5- 1 mg/kg) was given 
intravenously at the time of reperfusion of the graft and the 
methylprednisolone dosage was reduced in the first week 
to 1 mg/kg for the first month and then further reduced to 
0.2 mg/kg as maintenance. Azathioprine was continued for 
approximately 6 months. Rejection episodes were managed 
with 3 - 4 daily pulses of methylprednisolone, but increasingly 
this has not been required with early conversion to tacrolimus 
and selective use of mycophenolate mofetil. Recently anti-
CD25 antibodies have been used (basiliximab at 20 mg/dose 
for weight> 40 kg, 10 mg/dose for weight< 20 kg; daclizumab 
1 mg/kg/dose) both used as a 2-dose regimen.5 Rapamycin 
has also been used in two patients with chronic rejection, high 
Epstein-Barr virus (EBV) levels and associated post-transplant 
lymphoproliferative disease (PTLD). 
Infection prophylaxis."-10 Intravenous ampicillin and 
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cephalosporin is given at anaesthestic induction, repeated 
together with metronidazole at the time of biliary anastomosis 
and continued for 3 - 5 days peri-operatively. Antifungals in 
the form of oral mycostatin and amphotericin lozenges are 
given, and patients with severe cholestasis and prolonged 
pre-transplant inpatient treatment receive intravenous 
amphotericin peri-operatively for ± 2 weeks. Co-trimoxazole 
6 mg/kg/ day in 2 divided doses is given 3 days/week for 
prevention of Pneumocystis carinii infection and is continued 
for 6 months. Intravenous ganciclovir 5 mg/kg twice daily 
was given as viral prophylaxis against cytomegalovirus (CMV) 
and EBV infections, initially for 2 weeks, but since 1996 this is 
given for 3 months in children under the age of 3 and in high-
risk children not previously exposed to EBV in an attempt to 
prevent PTLDY In addition, Polygam is given intravenously 
for the first 5 days post transplant and all blood products are 
leucocyte filtered. TB prophylaxis is used in high-risk patients 
only. 
Results 
Since 1987, 84 orthotopic liver transplants have been performed 
on 81 children. All patients have survived the procedure and 
currently 60 (74%) patients have survived 3 months to 14 years 
post transplant. Fifty-one children have an excellent quality of 
life. 
The causes and timing of death are as follows: (i) early (::; 
1 month): sepsis (1), bleeding oesophageal ulcer (1), primary 
non-function (1), inferior vena cava (IVC) thrombosis (1), 
cerebral oedema (1); (ii) intermediate (> 1 - 6 months): rejection 
and associated sepsis (1), portal vein thrombosis with variceal 
bleed (1); (iii) late (> 6 months): bacterial, viral and fungal 
infections (5), PTLD (7), chronic rejection (2). 
Surgical complications 
Hepatic artery thrombosis occurred in 2 patients and portal 
vein thrombosis in 6 patients. Four patients developed early 
portal vein thrombosis ( < 6 months). In 2 patients, the portal 
vein thrombosis was successfully repaired and the third 
presented with an uncontrollable variceal bleed 6 months 
post transplant. Attempts at a Meso-Rex shunt and redo 
portal anastomosis failed in the fourth patient who remains 
clinically stable on enoxaparin sodium (Clexane) therapy. 
Two late portal vein thromboses occurred (> 1 year) resulting 
in portal hypertension and recurrent GIT bleeds. They were 
managed successfully with a Meso-Rex shunt. IVC thrombosis 
occurred in 2 patients and this was treated with thrombolytic 
therapy, which was successful in 1 patient (6 months post lim] 
transplant), but the second patient died from bleeding and 
sepsis in the peri-operative period. Bile leaks occurred in 4 
patients; in 2 these were successfully managed with revision of 
the biliary anastomosis and in the other 2 patients, the biliary 




spontaneously. Four patients developed postoperative GIT 
bleeding. Two required relook laparotomies, with the revision 
of Roux-en-Y anastomosis in 1, while the other patient was 
noted to have bleeding from the cut-surface of liver, which 
was cauterised. One patient's postoperative GIT bleeding 
settled spontaneously, and another patient presented with 
uncontrollable bleeding from a postsclerotherapy oesophageal 
ulcer. 
Medical complications 
Tuberculosis (3). Two children developed pulmonary 
tuberculosis and 1 patient a pleural effusion. TB drug treatment 
was complicated by chronic rejection in 1 patient and TB-drug-
induced subfulminant liver failure in 1 patient. 
De novo hepatitis B (5). Hepatitis B virus infection is 
endemic in South Africa with an HBsAg incidence of 3 - 20% 
and a HB IgG core Ab incidence of 40- 80%. Forty per cent of 
the potential donors are HB IgG core Ab-positive. Prior to 
1996, donors were only screened for HBsAg. Five children 
(6- 14 months post transplant) developed de novo hepatitis B. 
All had been HBsAg-negative pre-transplant and the explanted 
liver showed no evidence of hepatitis B infection. Three of 
the children had received organs from Hep B IgG core Ab-
positive donors and sera was not available for testing in 2. Two 
children have developed mild chronic hepatitis and 2 have 
developed severe chronic hepatitis progressing to cirrhosis. 
The DNA levels ranged between 1 920 and 4 800 pg/ml 
(mean 3 556 pg/ml). All patients were treated initially with 
famciclovir and then changed to lamivudine.12-14 Lamivudine 
resistance developed in 2 patients and 2 have died as a result of 
progressive chronic hepatitis B and complications of cirrhosis. 
One died soon after diagnosis from TB-drug-induced liver 
failure. 
CMV infection and disease. CMV infection is endemic in 
our population and 90% of donors were CMV-positive.15 CMV 
infection as defined by the presence of fever together with a 
positive culture or positive pp65Ag occurred in 12 patients 
and was treated successfully with intravenous ganciclovir. 
Ten patients developed CMV disease and the sites of disease 
included the lung (4), liver (7), pancreas and GIT (1). Five of 
the 10 patients with CMV disease have died. Risk factors for 
CMV infection and disease include poor nutritional status, 
high-dose steroids and pulsing. Since 1995, the regular use of 
CMV pp65Ag monitoring has enabled earlier diagnosis and 
treatment of CMV infection and consequently less disease. 
At present pre-emptive intravenous ganciclovir is given to all 
high-risk children and this has contributed to a decrease in the 
incidence of CMV disease. 
EBV and PTLD (12). EBV infection has resulted in 
significant morbidity and mortality in our children. Twelve 
children developed PTLD (all of them < 3 years of age) and 
the mean time to development of PTLD was 9.2 months 
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(range 3- 30 months post transplant). Eight had typical acute 
membranous tonsillitis with associated lymphadenopathy. 
Seven children were EBV nuclear antigen (EBNA)-positive at 
time of transplant and all were positive at time of diagnosis 
of PTLD. Sites of involvement include tonsils (8), intestine 
(6), mediastinum (4) and CNS (4). On histology, there were 6 
monoclonal, 2 oligoclonal and 4 polyclonal PTLD. Management 
of PTLD included the reduction of immunosuppression 
in all patients with complete withdrawal in 2 patients.10-11 
Adenotonsillectomy was performed in 7 patients and debulking 
surgery in 4. Of the 3 patients who received chemotherapy, all 
died within 10 weeks of diagnosis. Two patients have received 
intravenous rituximab. Seven patients died as a result of PTLD 
and 1 required a retransplant for chronic ductopenic rejection. 
Overall there was a 15% incidence of PTLD in our programme 
with a 58% mortality; despite the use of chemotherapy, 
reduction in immunosuppression and rituximab therapy. 
Survival 
The overall cumulative 1-year and 5-year patient survival is 
70% and 79% respectively. Since 1996, with the introduction of 
IVI ganciclovir for 3 months and the exclusion of HBV IgG core 
Ab-positive donors, the 1-year patient survival is 90% and the 
projected 5-year survival is> 80%. 
Discussion 
As the only established paediatric liver transplant centre within 
South Africa, children are referred from all over South Africa. 
In the early stages of our programme, children were referred in 
a pre-morbid clinical state and frequently died while awaiting 
a liver transplant. However, with increasing public awareness 
and education of the medical fraternity, children are now 
increasingly being referred early on in the course of their liver 
disease. Successful outcomes to liver transplantation however, 
are dependent on both a committed family and committed 
medical support, particularly when the child returns home to a 
medical centre in another province. 
Endemic viral and bacterial infections, particularly TB, CMV, 
EBV and hepatitis B have had a significant impact on our 
programme12•13•15-17 The recent ability to monitor CMV pp65 
Ag and EBV polymerase chain reaction (PCR) has enabled us 
to recognise viral infections earlier, treat appropriately and 
decrease immunosuppression. The de novo hepatitis B in the 5 
children was probably acquired as the result of using hepatitis 
B core Ab-positive donors.18 Two children have died as a 
result of chronic hepatitis B and 2 have developed lamivudine 
resistance. Since 1996, hepatitis B IgG core Ab-positive donors 
have been excluded as potential liver donors and no further 
cases of de novo hepatitis B have occurred. The hepatitis B IgG 
core Ab-positive rate in the donor pool is approximately 40% 
and this together with the increasing prevalence of HIV has 
significantly decreased the number of potential donors. 
ORIGINAL ARTICLES 
With the introduction of aggressive antiviral prophylactic 
regimens and the exclusion of hepatitis B core Ab-positive 
donors since 1996, the predicted 5-year patient survival 
figures are now greater than 80%, which is comparable with 
other reported series. Despite limited resources, diminishing 
manpower and a decreasing donor pool, the Red Cross 
Children's Hospital paediatric liver programme continues to 
be active with survival figures comparable with large centres 
elsewhere. With increasing public awareness, the number 
of children requiring transplantation will increase and at 
present split liver transplantation is beyond the capacity of our 
restricted manpower. Other options that need to be considered 
in expanding the donor pool are the increasing use of marginal 
donors and embarking on an active living-related programme. 
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